Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Inclusion Criteria: * Histologically confirmed unresectable AJCC stage III or stage IV melanoma * Patients must have metastatic melanoma with a resectable metastatic lesion(s) of sufficient size (≥ 2-3 cm in total) and must be willing to undergo such a resection for experimental purposes. * Patients should have received maximum one line of systemic therapy (except for ipilimumab) for unresectable or metastatic melanoma.\[ * Patients must be ≥ 18 years and ≤ 75 years of age and must have measurable disease by CT or MRI per RECIST 1.1 criteria (in addition to the resected lesion). * Patients must have a clinical performance status of ECOG 0 or 1. * Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for four months after receiving the preparative regimen. * Patients must be able to understand and sign the Informed Consent document. Exclusion Criteria: * Life expectancy of less than three months. * Patients with metastatic ocular/ mucosal or other non-cutaneous melanoma. * Adjuvant treatment with ipilimumab within 6 months prior to randomization. * Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to randomization. * Patients who have a more than two CNS metastases. * Patients who have any CNS lesion that is symptomatic, greater than 1 cm in diameter or show significant surrounding edema on MRI scan will not be eligible until they have been treated and demonstrated no clinical or radiologic CNS progression for at least 2 months. * All patients' toxicities due to prior non-systemic treatment must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures or focal palliative radiotherapy (to non-target lesions) within the past 4 weeks, as long as all toxicities have recovered to grade 1 or less. * Women who are pregnant or breastfeeding, because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. * Any active systemic infections, coagulation disorders or other active major medical illnesses. * Any autoimmune disease